Clinical trials
Clinically Significant Prostate Cancer clinical trials
Below are recruiting clinically significant prostate cancer clinical trials, each written for real people, not researchers. We’re tracking 311 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07614256Recruiting
Imaging and pathology analysis to predict prostate cancer
This study uses advanced imaging scans (MRI and ultrasound) and lab analysis of tissue samples to better predict prostate cancer. If you've had or are planning a prostate biopsy or surgery, your imaging and tissue results could help doctors develop better tools to diagnose prostate cancer.
Liuzhou, GuangxiAges 40–90 - NCT06706921RecruitingPhase 4
Predicting treatment success with PET scans in prostate cancer
This study looks at whether a special PET scan can help predict how well a targeted radiation therapy (LuPSMA) works in men with advanced prostate cancer that has spread. You would get several PET scans before and after treatment to see if the scan results can forecast your outcome.
Los Angeles, CaliforniaAges 18 years+ - NCT07581184RecruitingPhase 1
Targeted Radioactive Therapy for Advanced Prostate Cancer
This Phase 1 trial tests a new radioactive treatment called [225Ac]Ac-AKY-2519 in men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug carries radioactivity directly to cancer cells to try to shrink tumors and slow disease progression.
Irvine, CaliforniaAges 18 years+ - NCT07583160Enrolling by invitationPhase 1
YS247 Vaccine for Advanced Prostate Cancer
This trial tests a personalized cancer vaccine (YS247) designed to train your immune system to recognize and fight your prostate cancer. It may help slow or stop cancer growth in men whose cancer has spread and stopped responding to standard hormone treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07562438RecruitingPhase 2
Lutetium-177 Treatment for Advanced Prostate Cancer
This trial tests a radioactive medication (177Lu-P17-088) designed to target and treat prostate cancer that has spread to other parts of the body and stopped responding to hormone therapy. The medication is guided to cancer cells using a special imaging scan, potentially offering a new treatment option for men who have already tried other standard therapies.
Fuzhou, FujianAges 18–90 - NCT07553780Recruiting
Tracking Prostate Cancer Response Using PSMA Imaging Scans
This study uses a special type of imaging scan (PSMA PET) to track how well prostate cancer treatment is working by comparing scans before and after your planned therapy. The goal is to help doctors better understand which treatments work best for your type of cancer.
Lanzhou, GansuAges 18 years+ - NCT07545811RecruitingPhase 1
JANX014 for Advanced Prostate Cancer
This study tests a new immunotherapy drug called JANX014 in men with advanced prostate cancer that has stopped responding to hormone treatments. The trial aims to find the right dose and see if this drug can help slow or stop cancer growth.
La Jolla, CaliforniaAges 18 years+ - NCT07541911Recruiting
Confocal Microscopy to Check Prostate Cancer Surgery Margins
This study tests whether a special microscope can help surgeons see cancer margins (edges) during prostate removal surgery to make sure all cancer is removed. It may help surgeons make real-time decisions about how much tissue to remove.
LondonAges 18 years+ - NCT07531329Recruiting
Delayed PSMA imaging to detect aggressive prostate cancer
This study tests whether a special type of imaging scan (PSMA PET/CT with delayed imaging) can better identify aggressive prostate cancer in men who haven't had a biopsy yet. The goal is to help doctors decide who really needs a biopsy and avoid unnecessary procedures.
Lanzhou, GansuAges 18 years+ - NCT07492927Recruiting
Liquid biopsy for prostate cancer diagnosis
This study uses a blood test to detect prostate cancer more accurately than traditional methods. It looks for genetic material from cancer cells to help decide if a prostate biopsy is needed.
Chicago, IllinoisAges 18 years+ - NCT07441889RecruitingPhase 1/Phase 2
HER2-targeting immune cells for metastatic breast and prostate cancer
This trial tests a new treatment using specially designed immune cells that target HER2, a protein found on some cancer cells. It is for people with metastatic breast or prostate cancer that has worsened after prior treatments.
Charlottesville, VirginiaAges 18 years+ - NCT07432360Recruiting
Finding prostate cancer with advanced MRI and tissue analysis
This trial uses advanced MRI scans and detailed tissue analysis to better detect prostate cancer. It is for people with confirmed prostate cancer who are already scheduled for prostate removal surgery.
São PauloAges 18 years+ - NCT07414940RecruitingPhase 1/Phase 2
Actinium-225 PSMA for advanced prostate cancer after Lu-177
This trial tests a new targeted radiation drug called actinium-225 PSMA for men with advanced prostate cancer that has stopped responding to hormone therapy and has already been treated with Lu-177 PSMA (a similar targeted radiation therapy). It aims to see if this stronger radiation can help when the first type stops working.
LondonAges 18 years+ - NCT07341737RecruitingPhase 1/Phase 2
SL-28 for advanced solid tumors that haven’t responded to treatment
This trial tests a new drug, SL-28, for people with advanced solid tumors that haven’t responded to or cannot be treated with standard therapies. It aims to find a safe dose and see if the drug can help shrink or slow the growth of your cancer.
Sydney, New South WalesAges 18 years+ - NCT07339267RecruitingPhase 1
Safety and dosing study of ASP5541 in Chinese men with metastatic prostate cancer
This study tests a new drug called ASP5541 for Chinese men with prostate cancer that has spread. The drug is given as a shot, and researchers want to see if it is safe and what the right dose might be.
Beijing, Beijing MunicipalityAges 18–85 - NCT07339943Recruiting
Focal laser ablation for intermediate-risk prostate cancer
This trial tests a new way to treat intermediate-risk prostate cancer using a targeted laser guided by micro-ultrasound and MRI. It aims to see if this less invasive approach is safe and effective for men who have not had prior prostate cancer treatments.
Toronto, OntarioAges 40–85 - NCT06866782Recruiting
European study on advanced imaging for prostate cancer
This study is a European registry that collects information from men with prostate cancer who need advanced imaging (like PSMA PET/CT or MRI) to check if the cancer has spread. By joining, you help researchers learn more about how these scans improve care.
LeuvenAges 18 years+ - NCT07282808Recruiting
Focal vs. full prostate treatment study
This trial tests whether targeting only the visible cancer spots on MRI (focal therapy) works as well as treating the whole prostate, for men with small, moderate-risk prostate cancer that hasn't spread.
SingaporeAges 21 years+ - NCT07285057RecruitingPhase 2
New PET scan for men with low-risk prostate cancer on active surveillance
This trial tests a new imaging test called rhPSMA-7.3 (18F) PET/CT to see if it can better detect prostate cancer in men who are on active surveillance because their cancer is considered low-risk or favorable intermediate-risk. You would also get an MRI and a biopsy as part of the study.
New York, New YorkAges 18 years+ - NCT05344235Recruiting
Study of very short radiation schedules for prostate cancer
This observational study looks at how well men with localized prostate cancer do when treated with an unusually short radiation approach. It may help doctors understand which patients benefit most by tracking outcomes and imaging over time.
Leuven, Vlaams BrabantAges Any age - NCT07255664RecruitingPhase 1/Phase 2
TIL therapy for advanced colorectal or prostate cancer
This trial tests a new type of immunotherapy that uses your own white blood cells (TILs) to fight advanced colorectal or prostate cancer. You will have surgery to remove a tumor, then your TIL cells are grown in a lab and given back to you along with other treatments to boost your immune system.
FrankfurtAges 18 years+ - NCT06867588Recruiting
Adding PSMA PET to MRI for prostate cancer detection
This study is testing whether a special scan called a PSMA PET can help find significant prostate cancer in men who are already scheduled for an MRI-guided biopsy. It aims to see if combining the two scans gives a better picture of which prostate areas need to be biopsied.
BrusselsAges 18 years+ - NCT07237269RecruitingPhase 2
Abiraterone/prednisone plus ADT for early prostate cancer
This trial tests adding abiraterone (a hormone therapy pill) and prednisone to standard hormone therapy (ADT) for prostate cancer that has spread to nearby lymph nodes but is too small to see on regular scans. The goal is to see if this combination works better than ADT alone.
Omaha, NebraskaAges 30 years+ - NCT07230106RecruitingPhase 2
Study of 3 drugs for men with prostate cancer
This trial tests whether a combination of three new drugs (SHR3680, HS-20093, and SHR2554) can help slow or stop prostate cancer growth. It is for men who are already on hormone therapy and whose PSA level is still rising.
Nanjing, JiangsuAges 18–80
Hear when a new Clinically Significant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for clinically significant prostate cancer?
- Yes. Clin2 currently lists 311 recruiting clinically significant prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a clinically significant prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a clinically significant prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.